Patricia C Contreras
Overview
Explore the profile of Patricia C Contreras including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
217
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gracia-Sancho J, Manicardi N, Ortega-Ribera M, Maeso-Diaz R, Guixe-Muntet S, Fernandez-Iglesias A, et al.
Hepatol Commun
. 2019 Jul;
3(7):987-1000.
PMID: 31304452
In cirrhosis, liver microvascular dysfunction is a key factor increasing hepatic vascular resistance to portal blood flow, which leads to portal hypertension. De-regulated inflammatory and pro-apoptotic processes due to chronic...
2.
Kopec A, Spada A, Contreras P, Mackman N, Luyendyk J
Toxicol Sci
. 2017 Dec;
162(2):396-405.
PMID: 29228388
Tissue factor (TF) is the primary activator of the blood coagulation cascade. Liver parenchymal cells (ie, hepatocytes) express TF in a molecular state that lacks procoagulant activity. Hepatocyte apoptosis is...
3.
Verma V, Li H, Wang R, Hirsova P, Mushref M, Liu Y, et al.
J Hepatol
. 2015 Dec;
64(3):651-60.
PMID: 26632633
Background & Aims: The mechanisms by which hepatocyte exposure to alcohol activates inflammatory cells such as macrophages in alcoholic liver disease (ALD) are unclear. The role of released nano-sized membrane...
4.
Kahraman A, Bronk S, Cazanave S, Werneburg N, Mott J, Contreras P, et al.
Hepatol Res
. 2009 Jul;
39(8):805-13.
PMID: 19624765
Aim: Excessive matrix metalloproteinase (MMP) activity has been implicated in the pathogenesis of acute and chronic liver injury. CTS-1027 is an MMP inhibitor, which has previously been studied in humans...
5.
Hoglen N, Chen L, Fisher C, Hirakawa B, Groessl T, Contreras P
J Pharmacol Exp Ther
. 2004 Jan;
309(2):634-40.
PMID: 14742742
The potency, efficacy, and pharmacokinetic properties of IDN-6556 (3-[2-[(2-tert-butyl-phenylaminooxalyl)-amino]-propionylamino]-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid), a first-in-class caspase inhibitor in clinical trials for the treatment of liver diseases, were characterized in vivo in rodent models....